Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.

Introduction: Emicizumab is the first non-replacement therapy for prophylaxis in severe hemophilia A.

Aims: The principal aim of this study is to describe the results of our patients in prophylaxis with emicizumab, according to the usual clinical practice.

Material And Methods: Follow-up of 13 patients from the start of prophylaxis, recording of bleeding, surgeries, adverse reactions and the need or not for factor therapy.